| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1470-2045(15)00366-6 |
| P698 | PubMed publication ID | 26590673 |
| P50 | author | Mariusz Bidziński | Q20028388 |
| Isabelle Ray-Coquard | Q37995869 | ||
| Sandro Pignata | Q56419526 | ||
| Ignace Vergote | Q89808263 | ||
| Giovanni Scambia | Q91909477 | ||
| Felix Hilpert | Q124151001 | ||
| P2093 | author name string | Werner Meier | |
| Andreas du Bois | |||
| Philipp Harter | |||
| Nicoletta Colombo | |||
| Alain Lortholary | |||
| Susanne Malander | |||
| Line Bjørge | |||
| Jacobus Pfisterer | |||
| Gunnar Kristensen | |||
| Alexander Reuss | |||
| Mansoor R Mirza | |||
| Martin Heubner | |||
| Emmanuel Sevin | |||
| Maria O Nicoletto | |||
| Michael Merger | |||
| Petronella Ottevanger | |||
| Jose M Del Campo | |||
| Nikolaus de Gregorio | |||
| Martin Oliver Sailer | |||
| Ursula Denison | |||
| AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium | |||
| Thomas Minarik | |||
| P2860 | cites work | Targeting angiogenesis in gynecologic cancers | Q26824766 |
| BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy | Q27650860 | ||
| Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 | Q29615661 | ||
| Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup | Q30436714 | ||
| Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. | Q33333839 | ||
| Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study | Q33348987 | ||
| A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer | Q33399785 | ||
| Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial | Q33413609 | ||
| Incorporation of pazopanib in maintenance therapy of ovarian cancer | Q33417673 | ||
| A phase 3 trial of bevacizumab in ovarian cancer | Q34030022 | ||
| Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity | Q34580980 | ||
| Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial | Q34658812 | ||
| A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies | Q35011280 | ||
| Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial | Q36287626 | ||
| Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. | Q37811674 | ||
| 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference | Q37872164 | ||
| Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study | Q38964573 | ||
| Advanced Ovarian Cancer: Phase III Randomized Study of Sequential Cisplatin–Topotecan and Carboplatin–Paclitaxel vs Carboplatin–Paclitaxel | Q42862031 | ||
| Phase III Trial of Carboplatin Plus Paclitaxel With or Without Gemcitabine in First-Line Treatment of Epithelial Ovarian Cancer | Q42928480 | ||
| Incorporation of bevacizumab in the primary treatment of ovarian cancer | Q44579933 | ||
| Survival for ovarian cancer in Europe: the across-country variation did not shrink in the past decade | Q45891722 | ||
| Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer S | Q46966646 | ||
| Small sample inference for fixed effects from restricted maximum likelihood. | Q52255259 | ||
| Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. | Q53251965 | ||
| A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. | Q53298171 | ||
| Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. | Q54566293 | ||
| Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarial | Q83287534 | ||
| Bevacizumab in the treatment of ovarian cancer | Q84919012 | ||
| Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q86063198 | ||
| P433 | issue | 1 | |
| P921 | main subject | chemotherapy | Q974135 |
| ovarian cancer | Q172341 | ||
| placebo | Q269829 | ||
| phase III clinical trial | Q42824827 | ||
| P304 | page(s) | 78-89 | |
| P577 | publication date | 2015-11-13 | |
| P1433 | published in | Lancet Oncology Commission | Q13747613 |
| P1476 | title | Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial | |
| P478 | volume | 17 |
| Q50080825 | A synthetic lethal bullet |
| Q48104995 | Advances in ovarian cancer therapy |
| Q55217694 | Angiogenesis Inhibitors for the Treatment of Ovarian Cancer: An Updated Systematic Review and Meta-analysis of Randomized Controlled Trials. |
| Q38872239 | Anti-angiogenic agents in ovarian cancer: past, present, and future. |
| Q58706801 | Antiangiogenesis therapy in ovarian cancer patients: An updated meta-analysis for 15 randomized controlled trials |
| Q28073722 | Antiangiogenic therapies in ovarian cancer |
| Q92548235 | Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysis |
| Q38822258 | Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial |
| Q92035335 | Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial |
| Q98158111 | Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study |
| Q57456582 | Cardiovascular Toxicities with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Meta-Analysis of 77 Randomized Controlled Trials |
| Q37094042 | Characterization of FGFR signaling pathway as therapeutic targets for sarcoma patients |
| Q90736221 | Comparing Paclitaxel-Carboplatin with Paclitaxel-Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer |
| Q93355703 | Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12 |
| Q90322004 | Epidermal growth factor receptor/heme oxygenase-1 axis is involved in chemoresistance to cisplatin and pirarubicin in HepG2 cell lines and hepatoblastoma specimens |
| Q38874036 | FIGO stage IV epithelial ovarian, fallopian tube and peritoneal cancer revisited |
| Q52584387 | First-line treatment of ovarian cancer: questions and controversies to address. |
| Q37512962 | Focus on Nintedanib in NSCLC and Other Tumors |
| Q49895978 | Front-line therapy of advanced epithelial ovarian cancer: standard treatment |
| Q47323988 | Front-line therapy of advanced ovarian cancer: new approaches |
| Q92906903 | Immune Heterogeneity Between Primary Tumors and Corresponding Metastatic Lesions and Response to Platinum Therapy in Primary Ovarian Cancer |
| Q33563488 | Inhibition of lymphangiogenesis in vitro and in vivo by the multikinase inhibitor nintedanib |
| Q65000120 | Long-term progression-free survival of apatinib monotherapy for relapsed ovarian cancer: a case report and literature review. |
| Q28077183 | Major clinical research advances in gynecologic cancer in 2015 |
| Q33563963 | Major clinical research advances in gynecologic cancer in 2016: 10-year special edition |
| Q26741755 | Management of relapsed ovarian cancer: a review |
| Q94046968 | MicroRNAs as Key Regulators of Ovarian Cancers |
| Q64121576 | Molecular Characterization of Non-responders to Chemotherapy in Serous Ovarian Cancer |
| Q42347314 | Negative trials in ovarian cancer: is there such a thing as too much optimism? |
| Q92618072 | Neurofibromin 1 expression is negatively correlated with malignancy and prognosis of epithelial ovarian cancer |
| Q90237649 | Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study |
| Q51824301 | Nintedanib in ovarian cancer. |
| Q64284104 | Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition |
| Q88195269 | Ovarian cancer |
| Q90098861 | Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer |
| Q92567882 | Overexpression of microRNA-195-5p reduces cisplatin resistance and angiogenesis in ovarian cancer by inhibiting the PSAT1-dependent GSK3β/β-catenin signaling pathway |
| Q90029904 | Patient Experience Captured by Quality-of-Life Measurement in Oncology Clinical Trials |
| Q37544401 | Phase I study of nintedanib in Japanese patients with advanced hepatocellular carcinoma and liver impairment |
| Q92726174 | Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer |
| Q30249619 | Risk of selected gastrointestinal and hepatic toxicities in cancer patients treated with nintedanib: a meta-analysis. |
| Q47719824 | Safety and efficacy of nintedanib for the treatment of metastatic colorectal cancer |
| Q33885479 | Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study |
| Q31125419 | Same Data; Different Interpretations |
| Q56957787 | Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial |
| Q47370432 | Synthetically lethal nanoparticles for treatment of endometrial cancer. |
| Q47685928 | Targeted Therapies in the Management of Ovarian Cancer: A Focus on Older Patients |
| Q38760610 | Targeted agents and combinations in ovarian cancer: where are we now? |
| Q98164379 | Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence |
| Q58789499 | Targeting the Microenvironment in High Grade Serous Ovarian Cancer |
| Q41619260 | Thalidomide and lenalidomide for recurrent ovarian cancer: A systematic review of the literature |
| Q49966031 | The role of Cediranib in ovarian cancer |
| Q52645823 | The role of tumor microenvironment in resistance to anti-angiogenic therapy. |
| Q61818032 | Therapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancers |
| Q50042447 | Therapeutic impact of nanoparticle therapy targeting tumor-associated macrophages |
| Q64109213 | Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial |
| Q98771756 | Tumor Microenvironment in Ovarian Cancer: Function and Therapeutic Strategy |
| Q90342385 | Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer |
| Q91645432 | Weekly Dose-Dense Paclitaxel and Triweekly Low-Dose Cisplatin: A Well-Tolerated and Effective Chemotherapeutic Regimen for First-Line Treatment of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer |
Search more.